Clinical trial NCT04548037: Assessment of Emotional Memory During Transient Global Amnesia
Official title: Assessment of Emotional Memory During Transient Global Amnesia
Study type: OBSERVATIONAL
Overall status: TERMINATED
Conditions: Amnesia, Transient Global
Lead sponsor: Centre Hospitalier Universitaire de Nīmes
Sponsor class: OTHER
First posted: 2020-09-14
Enrollment: 2
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: CASE_CONTROL
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Adult patients with a transient global amnesia according to the criteria of Hodges and Warlow (1990) in the acute phase (i.e. within 24 hours after the onset of the stroke), accompanied by a trusted person and admitted to the SAU of the CHU de Nîmes, plus a group of healthy volunteers.

Brief summary: There are few studies on the role played by emotions in transient global amnesia (TGA), in particular with regard to their impact on the functioning of memory. The study investigators wish to better understand the link between episodic memory, emotional state and psychogenic factors during TGA. It would be interesting to see if the patients suffering from TGA triggered by a psychological shock process emotional information differently from those whose TGA was triggered by an "organic" shock (physical effort, trauma, etc.). Finally, amnesic stroke is a good model for better understanding the function of the hippocampus, in particular of the CA1 region, in episodic memory.


Eligibility criteria: Inclusion Criteria:

* Subject with no history of transient global amnesia or neurological or psychiatric pathology.
* Patients with a transient global amnesia according to the criteria of Hodges and Warlow (1990) in the acute phase (i.e. within 24 hours after the onset of the stroke), accompanied by a trusted person
* The patient must have given their free and informed consent and signed the consent form
* The patient must be a member or beneficiary of a health insurance plan

Exclusion Criteria:

* The subject is participating in another study, or is in a period of exclusion determined by a previous study
* The subject refuses to sign the consent
* It is impossible to give the subject informed information
* The patient is under safeguard of justice or state guardianship
* The patient is pregnant or breastfeeding
* Presence of a focal neurological pathology that may explain the symptoms, history of epilepsy or psychiatric disorders.
* Hypersensitivity to iodinated contrast media.
* Known allergy to 18-FDG.

Non-inclusion criteria concerning control subjects:

* Presence of disorders on neurological assessment
* Presence of cognitive disorders on the neuropsychological assessment (z-score \<-1.65 on the RBANS or on the Stroop test).

Exclusion criteria for the target population:

• Patients will be excluded after the 1st neuropsychological assessment if episodic memory tests show complete recovery from anterograde amnesia.

Primary outcomes:
measure: Storage and retrieval capacities of information with a strong emotional valence in patients compared to healthy controls
timeFrame: Day 0
measure: Ability to judge the degree of activation and emotional value associated with images
timeFrame: Day 0
Secondary outcomes:
measure: Change in storage and retrieval capacities of information with a strong emotional valence in patients from baseline
timeFrame: Day 3
measure: Change in storage and retrieval capacities of information with a strong emotional valence in patients from baseline
timeFrame: Month 3
measure: Classification of event triggering transient global amnesia
timeFrame: Day 0
measure: Anxiety
timeFrame: Day 0
measure: Depression
timeFrame: Day 0
measure: Mood
timeFrame: Day 0
measure: C-score of the Groupe de REflexion pour l'Evaluation des Fonctions Exécutives (GREFEX) version of Stroop Test between patients and healthy control
timeFrame: Day 0
measure: Repeatable Battery for the Assessment of Neuropsychological Status between patients and healthy control
timeFrame: Day 0
measure: Identification of hypometablic zones by PET compared to age- and sex-matched controls
timeFrame: Day 0
Other outcomes:
Locations:
city: Nîmes
country: France
facility: CHU de Nimes
Study officials:
affiliation: CHU Nimes
name: Eric THOUVENOT
role: PRINCIPAL_INVESTIGATOR
References: